Variation in accumulated dose of volumetric‐modulated arc therapy for pancreatic cancer due to different beam starting phases

Purpose To assess the effects of different beam starting phases on dosimetric variations in the clinical target volume (CTV) and organs at risk (OARs), and to identify the relationship between plan complexity and the dosimetric impact of interplay effects in volumetric‐modulated arc therapy (VMAT) plans for pancreatic cancer.